0.587
price down icon6.53%   -0.041
after-market 시간 외 거래: .57 -0.017 -2.90%
loading
전일 마감가:
$0.628
열려 있는:
$0.6
하루 거래량:
94,475
Relative Volume:
0.15
시가총액:
$19.18M
수익:
-
순이익/손실:
-
주가수익비율:
-6.6553
EPS:
-0.0882
순현금흐름:
-
1주 성능:
-16.14%
1개월 성능:
-5.22%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
Value
$0.55
$0.6325
1주일 범위
Value
$0.55
$0.675
52주 변동 폭
Value
$0.55
$19.51

Jupiter Neurosciences Inc Stock (JUNS) Company Profile

Name
명칭
Jupiter Neurosciences Inc
Name
전화
(561) 406-6154
Name
주소
1001 NORTH US HWY 1, JUPITER
Name
직원
5
Name
트위터
Name
다음 수익 날짜
Name
최신 SEC 제출 서류
Name
JUNS's Discussions on Twitter

JUNS을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
JUNS
Jupiter Neurosciences Inc
0.587 19.18M 0 0 0 -0.0882
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
474.62 125.40B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
573.45 65.79B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
555.11 35.18B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
235.74 32.67B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
238.51 26.46B 3.81B -644.79M -669.77M -6.24

Jupiter Neurosciences Inc 주식(JUNS)의 최신 뉴스

pulisher
Mar 28, 2025

Jupiter Neurosciences Inc. (JUNS) reports earnings - Quartz

Mar 28, 2025
pulisher
Mar 25, 2025

Jupiter Neurosciences faces NASDAQ delisting over share price By Investing.com - Investing.com South Africa

Mar 25, 2025
pulisher
Mar 25, 2025

Jupiter Neurosciences faces NASDAQ delisting over share price - Investing.com

Mar 25, 2025
pulisher
Mar 18, 2025

Jupiter Neurosciences, Catalent Partner to Produce JOTROL Softgels for Upcoming Trial - Contract Pharma

Mar 18, 2025
pulisher
Mar 07, 2025

Alliance Entertainment and Jupiter Neurosciences Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Bluefield Daily Telegraph

Mar 07, 2025
pulisher
Mar 04, 2025

Jupiter Neurosciences and Aquanova AG Announce Strategic - GlobeNewswire

Mar 04, 2025
pulisher
Mar 04, 2025

Jupiter Neurosciences, Aquanova announce strategic collaboration - TipRanks

Mar 04, 2025
pulisher
Mar 04, 2025

Jupiter Neurosciences partners with Aquanova on health products By Investing.com - Investing.com South Africa

Mar 04, 2025
pulisher
Mar 04, 2025

Jupiter Neurosciences And Aquanova AG Announce Strategic Collaboration To Develop Longevity And Healthspan Products - Marketscreener.com

Mar 04, 2025
pulisher
Mar 04, 2025

Jupiter Neurosciences partners with Aquanova on health products - Investing.com

Mar 04, 2025
pulisher
Mar 04, 2025

Can Jupiter Neurosciences Capture The $44B Longevity Market With Its New Aquanova Partnership? - StockTitan

Mar 04, 2025
pulisher
Feb 10, 2025

Jupiter Neurosciences Inc (JUNS) Shares Decline Despite Market Challenges - The News Heater

Feb 10, 2025
pulisher
Feb 10, 2025

Jupiter Neurosciences partners with Catalent for Parkinson’s trial By Investing.com - Investing.com Nigeria

Feb 10, 2025
pulisher
Feb 07, 2025

Three technology stocks with differentiated value propositions | 2025-02-07 | Investing News - Stockhouse Publishing

Feb 07, 2025
pulisher
Feb 07, 2025

Jupiter Neurosciences partners with Catalent for Parkinson's trial - MSN

Feb 07, 2025
pulisher
Feb 04, 2025

Jupiter Neurosciences Addresses Market Volatility as it - GlobeNewswire

Feb 04, 2025
pulisher
Feb 04, 2025

Jupiter Neurosciences says volatility ‘appears to be driven by misconceptions’ - TipRanks

Feb 04, 2025
pulisher
Feb 04, 2025

Jupiter Neurosciences Addresses Market Volatility as it Remains Focused on Advancing Clinical and Commercial Milestones - TradingView

Feb 04, 2025
pulisher
Feb 04, 2025

Inside Jupiter's $50B Market Strategy: NIH Funding Secured, Phase 2 Trials Set for Revolutionary CNS Treatment - Stock Titan

Feb 04, 2025
pulisher
Feb 03, 2025

Jupiter Neurosciences Partners With Catalent For Parkinson's JOTROL Trial Production - Nasdaq

Feb 03, 2025
pulisher
Feb 03, 2025

Jupiter Neurosciences Signs Manufacturing Deal With Catalent Pharma for Jotrol Softgel Capsules - Marketscreener.com

Feb 03, 2025
pulisher
Feb 03, 2025

Jupiter Neurosciences Partners with Catalent to Produce JOTROL Softgels for Upcoming Clinical Trial - Contract Pharma

Feb 03, 2025
pulisher
Feb 03, 2025

Jupiter Neurosciences partners with Catalent for Parkinson's trial By Investing.com - Investing.com South Africa

Feb 03, 2025
pulisher
Feb 03, 2025

Clinical Trials News Live Feed - StockTitan

Feb 03, 2025
pulisher
Feb 03, 2025

Jupiter Neurosciences Announces JOTROL Manufacturing - GlobeNewswire

Feb 03, 2025
pulisher
Feb 03, 2025

Jupiter Neurosciences Announces JOTROL Manufacturing Agreement with Catalent to Support Phase 2a Parkinson's Trial - The Manila Times

Feb 03, 2025
pulisher
Feb 03, 2025

Major Breakthrough: New Parkinson's Drug Manufacturing Deal Could Fast-Track Treatment for 10M Patients - StockTitan

Feb 03, 2025
pulisher
Feb 03, 2025

Phase 2a trial of Jotrol as treatment for Parkinson’s planned - Parkinson's News Today

Feb 03, 2025
pulisher
Jan 31, 2025

Jupiter Neurosciences partners with Zina for Parkinson's trial - Investing.com India

Jan 31, 2025
pulisher
Jan 30, 2025

Jupiter Neurosciences, Zina Biopharmaceuticals Collaborate on Phase 2a Parkinson's Disease Study - Marketscreener.com

Jan 30, 2025
pulisher
Jan 30, 2025

Jupiter Neurosciences Partners with Zina Biopharmaceuticals to Advance Phase 2a Parkinson’s Trial - GlobeNewswire

Jan 30, 2025
pulisher
Jan 30, 2025

Jupiter Neurosciences partners with Zina for Parkinson's trial By Investing.com - Investing.com South Africa

Jan 30, 2025
pulisher
Jan 30, 2025

Jupiter Neurosciences Partners With Zina Biopharmaceuticals To Launch Phase 2a Parkinson's Trial - Nasdaq

Jan 30, 2025
pulisher
Jan 24, 2025

Wall Street Set to Open Slightly Lower Friday as Investors Await PMI, Housing Figures - TradingView

Jan 24, 2025
pulisher
Jan 24, 2025

12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga

Jan 24, 2025
pulisher
Jan 24, 2025

United States shares higher at close of trade; Dow Jones Industrial Average up 0.93% - Investing.com India

Jan 24, 2025
pulisher
Jan 23, 2025

U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.93% - Investing.com

Jan 23, 2025
pulisher
Jan 23, 2025

U.S. shares higher at close of trade; Dow Jones Industrial Average up 0.93% - Investing.com UK

Jan 23, 2025
pulisher
Jan 23, 2025

12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga

Jan 23, 2025
pulisher
Jan 23, 2025

Stock market news: Chanson International Holdings declined by 83.97% while Dogwood Therapeutics surged by 387.32% during mid day trading - Business Upturn

Jan 23, 2025
pulisher
Jan 23, 2025

Stock market today: Icon Energy surged by 222.66% while Jupiter Neurosciences gained over 208.62% in early trading - Business Upturn

Jan 23, 2025
pulisher
Jan 23, 2025

US Stocks Mixed; GE Aerospace Posts Upbeat Earnings - Benzinga

Jan 23, 2025
pulisher
Jan 23, 2025

Modest Final Quarter Completes Shaky Biotech IPO Comeback For 2024 - News & Insights

Jan 23, 2025
pulisher
Jan 22, 2025

Stock market news: Star Fashion Culture Holdings -78.42%, Lisata Therapeutics -33.08% among biggest losers in early trading - Business Upturn

Jan 22, 2025
pulisher
Jan 22, 2025

Stock market today: Star Fashion Culture Holdings -79.05%, Lisata Therapeutics -23.34% among biggest losers in early trading - Business Upturn

Jan 22, 2025
pulisher
Jan 21, 2025

Twin Vee PowerCats Co. New 5-Axis CNC Router to Harness Advanced Robotics in Production Process - The Globe and Mail

Jan 21, 2025
pulisher
Jan 14, 2025

Biopharma IPOs rebound slightly, as class of 2024 lags with a 29% average decline - BioWorld Online

Jan 14, 2025
pulisher
Jan 13, 2025

Jupiter Neurosciences refocuses on NLRP3 inflammasome By Investing.com - Investing.com South Africa

Jan 13, 2025
pulisher
Jan 13, 2025

Jupiter Neurosciences refocuses on NLRP3 inflammasome - Investing.com India

Jan 13, 2025
pulisher
Jan 13, 2025

Jupiter Neurosciences Announces Strategic Focus on NLRP3 Pathway in Future JOTROL™ Trials - GlobeNewswire

Jan 13, 2025
pulisher
Jan 13, 2025

Jupiter Neurosciences announces focus on NLRP3 pathway in JOTROL trials - TipRanks

Jan 13, 2025

Jupiter Neurosciences Inc (JUNS) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$60.26
price down icon 10.70%
$69.18
price down icon 5.66%
$17.36
price down icon 8.20%
$31.11
price down icon 2.14%
$88.05
price down icon 4.30%
biotechnology ONC
$238.51
price down icon 9.76%
자본화:     |  볼륨(24시간):